DE60027268D1 - Pyroglutaminsäurederivate und damit verwandte verbindungen, die die durch vla-4 vermittelte leukozytenadhäsion verringern - Google Patents

Pyroglutaminsäurederivate und damit verwandte verbindungen, die die durch vla-4 vermittelte leukozytenadhäsion verringern

Info

Publication number
DE60027268D1
DE60027268D1 DE60027268T DE60027268T DE60027268D1 DE 60027268 D1 DE60027268 D1 DE 60027268D1 DE 60027268 T DE60027268 T DE 60027268T DE 60027268 T DE60027268 T DE 60027268T DE 60027268 D1 DE60027268 D1 DE 60027268D1
Authority
DE
Germany
Prior art keywords
leukocytadhesion
vla
evaluated
reduce
acid derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60027268T
Other languages
English (en)
Other versions
DE60027268T2 (de
Inventor
B Dressen
Anthony Kreft
Dennis Kubrak
William Mann
A Pleiss
Paul Stack
D Thorsett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Elan Pharmaceuticals LLC
Original Assignee
Wyeth LLC
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC, Elan Pharmaceuticals LLC filed Critical Wyeth LLC
Publication of DE60027268D1 publication Critical patent/DE60027268D1/de
Application granted granted Critical
Publication of DE60027268T2 publication Critical patent/DE60027268T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06173—Dipeptides with the first amino acid being heterocyclic and Glp-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60027268T 1999-01-26 2000-01-21 Pyroglutaminsäurederivate und damit verwandte verbindungen, die die durch vla-4 vermittelte leukozytenadhäsion verringern Expired - Fee Related DE60027268T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23866199A 1999-01-26 1999-01-26
US238661 1999-01-26
PCT/US2000/001537 WO2000043413A2 (en) 1999-01-26 2000-01-21 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (2)

Publication Number Publication Date
DE60027268D1 true DE60027268D1 (de) 2006-05-24
DE60027268T2 DE60027268T2 (de) 2007-03-15

Family

ID=22898814

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60027268T Expired - Fee Related DE60027268T2 (de) 1999-01-26 2000-01-21 Pyroglutaminsäurederivate und damit verwandte verbindungen, die die durch vla-4 vermittelte leukozytenadhäsion verringern

Country Status (12)

Country Link
EP (2) EP1612215A1 (de)
JP (1) JP2002535341A (de)
CN (1) CN1195773C (de)
AR (1) AR022405A1 (de)
AT (1) ATE323102T1 (de)
AU (1) AU2623800A (de)
CA (1) CA2358093A1 (de)
DE (1) DE60027268T2 (de)
ES (1) ES2262504T3 (de)
HK (1) HK1046146B (de)
TW (1) TWI224110B (de)
WO (1) WO2000043413A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1612215A1 (de) * 1999-01-26 2006-01-04 Elan Pharmaceuticals, Inc. Pyroglutaminsäurederivate und damit verwandte Verbindungen, die die durch VLA-4 vermittelte Leukozytenadhäsion verringern
US6407066B1 (en) * 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
JP5401218B2 (ja) * 2009-09-03 2014-01-29 東京応化工業株式会社 レジスト組成物、レジストパターン形成方法
CN108299218A (zh) * 2017-01-12 2018-07-20 南京红杉生物科技有限公司 一种4-溴-d-苯丙氨酸的合成方法
CN109180552B (zh) * 2018-09-26 2021-10-26 沈阳药科大学 取代的5-氧代吡咯烷类衍生物及其制备方法和应用
JP7189369B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４β７インテグリンの阻害のための化合物
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
JP7189368B2 (ja) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリンの阻害のための化合物
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE237342T1 (de) * 1994-07-11 2003-05-15 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
IL163521A0 (en) * 1996-06-21 2005-12-18 Takeda Pharmaceutical Method for producing peptides and their salts which have an agonist activity of luteinizing hormone releasing hormones secretesd from the hypot
BR9812111A (pt) * 1997-07-31 2000-07-18 Elan Pharm Inc Dipeptìdeo e compostos correlatos que inibem adesão de leucócito mediada por vla-4
TW591026B (en) * 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
EP1612215A1 (de) * 1999-01-26 2006-01-04 Elan Pharmaceuticals, Inc. Pyroglutaminsäurederivate und damit verwandte Verbindungen, die die durch VLA-4 vermittelte Leukozytenadhäsion verringern

Also Published As

Publication number Publication date
ATE323102T1 (de) 2006-04-15
HK1046146A1 (en) 2002-12-27
CN1344274A (zh) 2002-04-10
JP2002535341A (ja) 2002-10-22
EP1612215A1 (de) 2006-01-04
HK1046146B (zh) 2005-07-29
WO2000043413A2 (en) 2000-07-27
CN1195773C (zh) 2005-04-06
TWI224110B (en) 2004-11-21
EP1144435B1 (de) 2006-04-12
WO2000043413A3 (en) 2000-11-30
CA2358093A1 (en) 2000-07-27
EP1144435A2 (de) 2001-10-17
DE60027268T2 (de) 2007-03-15
AU2623800A (en) 2000-08-07
AR022405A1 (es) 2002-09-04
ES2262504T3 (es) 2006-12-01

Similar Documents

Publication Publication Date Title
SI1429761T1 (sl) Novi 4,5-dihidro-1h-pirazolni derivati s cb1-antagonisticno aktivnostjo
AP2002002529A0 (en) 2,4-Diaminopyrimidine compounds useful as immunosupressants
SI1373216T1 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
NL1014361A1 (nl) Bevestigingsorgaan.
HK1054026A1 (en) Substituted piperidines, medicaments containing these compounds, and methods for the production thereof.
MXPA03009645A (es) Proceso para preparar oxazolidinonas.
DE60027268D1 (de) Pyroglutaminsäurederivate und damit verwandte verbindungen, die die durch vla-4 vermittelte leukozytenadhäsion verringern
IT1311921B1 (it) Composti farmaceutici.
NL1013172A1 (nl) Schroefboutbevestiging.
BR0004161B1 (pt) solução de molho ácido.
MXPA03002926A (es) Proceso para la sintesis de 2,2,6,6,-tetrametil-4--oxipiperidina.
AP2005003247A0 (en) Acetyl 2-hydroxy-1,3 diaminoalkanes.
RU98116380A (ru) Применение ингибиторов натрий-водородного обмена для получения лекарственного средства в целях лечения заболеваний, вызываемых простейшими
EG23417A (en) Process for the preparation 7 a-methylsteroids.
BR0013094B1 (pt) processo para a preparação de compostos 1,3-dicarbonìlicos acilados.
HK1046133A1 (en) Pharmaceutical compounds.
HUP0002147A3 (en) Hydroxybenzoic acid derivatives, process for producing them and pharmaceutical compositions having antiplasmid activity comprising the said compounds
ITTO20000542A0 (it) Letto, particolarmente per veicoli.
MXPA03006932A (es) Derivado de indolina y procedimiento para la produccion del mismo.
ES1050698Y (es) Cerramiento perfeccionado.
MXPA03008636A (es) Derivados de isoquinuclidina, metodo para fabricar los mismos y agentes terapeuticos que contienen estos compuestos.
IT247783Y1 (it) Struttura di chiusura particolarmente per fibbie.
ES1048370Y (es) Maquina trituradora de desperdicios perfeccionada.
ES1049102Y (es) Tope sujeta puertas perfeccionado.
ES1044056Y (es) Cerradura de picaporte perfeccionada.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee